BioSpace News Archive

ATAI Life Sciences AG, a global biotechnology company builder that envisions an end to mental illnesses, has acquired a majority stake in New York-based pharmaceutical company Kures, which targets the important intersection between pain and opioid use disorder

NeuroMetrix, Inc. (Nasdaq: NURO) today announced expanded distribution in China for DPNCheck, a fast, accurate and quantitative nerve conduction test for evaluation of peripheral neuropathies such as diabetic peripheral neuropathy (DPN).

The use of duplex sequencing to improve DNA sequencing accuracy may gain considerable momentum and serve as a prime growth generator for the growth of the duplex sequencing market across the forecast period of 2019-2029.

AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today preliminary unaudited results for the fourth quarter and full year ended June 30, 2020, together with a company update. Preliminary Unaudited Results f

First outside investment to accelerate on-demand access to world-leading, non-invasive brain recording technology

Virpax® Pharmaceuticals Inc. (“Virpax”), a company specializing in developing pharmaceutical products that incorporate the use of novel drug delivery systems for pain management, today announced the election of Vanila M. Singh, MD, MACM, to its Board of Directors.

DRADS Capital announced its investment in ROKIT Healthcare Inc., a South Korean biotechnology company developing innovative 4D bioprinting techniques and applications, in its Series C funding round of undisclosed amount.

Imbio, a healthcare technology company developing the leading suite of medical image analysis for pulmonary and cardiothoracic diseases, announced today that their FDA-cleared solutions will be available on the Nuance AI Marketplace,

Data Focused on Biomarkers of Neuroinflammation will be Topic of Key Opinion Leaders Call Set for July 14 at 8:00 AM Eastern Time

Otonomy, Inc. announced the pricing of an underwritten public offering of 14,500,000 shares of its common stock at a price to the public of $3.25 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to an aggregate of 4,000,000 shares of its common stock at a purchase price of $3.249 per each pre-funded warrant...